BioStock published an article on 22 June 2022 about Cyxone, which can be read in full below. The board of Malmö-based company Cyxone recently announced a change in management. Carl-Magnus Högerkorp, Chief Operating Officer, steps in as acting CEO...
Read MoreBioStock published an article on 20 May 2022 about Cyxone, which can be read in full below. First North-listed Cyxone recently published its Q1 report, a period during which the company carried out a rights issue of 61 MSEK,...
Read MoreBioStock published an article on 5 May 2022 about the great need of new treatment options for RA patients. Following the FDA’s safety warnings, a shift is seen away from JAK inhibitors for the treatment of rheumatoid arthritis. The...
Read MoreBioStock published an article on 7 February 2022 about Cyxone, which can be read in full below. Biotech company Cyxone recently announced the next step in the T20K project, their drug candidate for multiple sclerosis. The company has signed...
Read MoreBioStock published an article on 20 December 2021 about Cyxone, which can be read in full below. In the preparation for the coming phase IIb trial with Rabeximod in rheumatoid arthritis, biotech company Cyxone has entered an Early Operations...
Read MoreBioStock published an article on 8 November 2021 about Cyxone, which can be read in full below. Biotech company Cyxone is developing T20K, a drug candidate with first-in-class potential for the treatment of multiple sclerosis. Recently, Cyxone’s research partner,...
Read MoreIt is time for 2021’s edition of the largest partnering meeting in the life science space – BIO-Europe. This week, representatives from nearly 1,500 companies will gather to establish new contacts as well as continue initiated discussions with potential...
Read MoreBioStock published an article on 16 August 2021 about Cyxone, which can be read in full below. Swedish biotech Cyxone announced last month that the patient recruitment for its phase II trial testing Rabeximod in Covid-19 could come to...
Read MoreBioStock published an article on 15 July 2021 about Cyxone, which can be read in full below. After identifying new therapeutic treatment possibilities for T20K, Cyxone has announced a research collaboration with the Medical University of Vienna to further...
Read MoreBioStock published an article on 14 June 2021 about Cyxone, which can be read in full below. During May, Swedish biotech company Cyxone released a string of news. Recently, the company announced the recruitment of Carl-Magnus Högerkorp as new...
Read More